Recently, the anti-cancer efficacy of antibodies against PD-1/programmed cell death ligand 1 (PD-L1) via T-cell checkpoint blockade in obese cancer patients [5] and non-small cell lung cancer [6]. This evidence concerns the gene PDCD1 and cancer.